Genmab — Maj 2015
-
Fra Nordea i eftermiddag "Efter et møde i dag med Genmabs CEO er vi blevet yderligere bekræftet i, at vi vil få
stærke data på selskabets hovedprodukt at se om en uges tid, når der er konference i
den amerikanske cancerorganisation. Det underbygger vores positive holdning til aktien."
-
-
Og ekstra understøttelse af Ofa i maintenance er da også OK: These results clearly demonstrate that ofatumumab maintenance therapy does not negatively affect HRQoL: http://learningcenter.ehaweb.org/eha/2015/20th/100467/stephanie.manson.health.related.quality.of.life.and.patient.reported.outcomes.html?f=p3m3
-
nej celsius
-
jeg spurgte også Rachel om phase Ib data til EHA ville være opdateret fra ASH
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind